Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected ...

Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million Topline results expected in 2Q 2025 ...

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

With no known cure, he opted for voluntary assisted dying after his condition became unbearable, accompanied by excruciating ...

A new FDA-approved ATTR-CM treatment is giving new hope to patients — especially older Black Americans who are at high risk ...

The journalist’s organs had been severely damaged by the disease, which causes a buildup of amyloid proteins in the body.

After a long career as an accomplished TV and radio journalist for programs like AM, This Day Tonight and Beyond 2000, Iain ...

ALNY reports better-than-expected first-quarter results as both earnings and revenues beat estimates, driven by higher product sales.

The European Medicines Agency has recommended marketing approval for Alyftrek for cystic fibrosis and Attrogy for a form of hereditary amyloidosis.

Prothena today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025.

In its 10-Q report, Alnylam Pharmaceuticals stated that as of March 31, 2025, it had an accumulated deficit of $7.35 billion ...